Webinar: Current state of digital health solutions: Introducing a mobile-only approach to heart health monitoring
This webinar was held on January 25, 2022.
Advances in digital health and mobile technology provide a major opportunity to broaden the reach of health care to at-risk individuals.
In this webinar led by CardioSignal’s Chief Medical Officer Tero-Pekka Alastalo, we review the current state of digital health solutions in early detection of heart disease. As the population ages, atrial fibrillation (AF) alone is predicted to affect 6–12 million people in the USA by 2050 and 17.9 million in Europe by 2060. With heart disease numbers only rising, we are facing a health and economic problem described as an epidemic by researchers and physicians around the world.
Digital health solutions have the potential to dramatically improve patient care and slow rising costs. Yet achieving scalability has obstacles as there are no technologies available for effective and scalable screening in risk populations.
Webinar objectives:
Review the current state of digital health solutions and their benefits and challenges from primary care perspective
Introduce a motion sensor technology that utilizes modern smartphone technology
Give an overview of clinical studies and clinical validation of gyrocardiography technology
Present data from current user base of the technology
Evaluate the capabilities of gyrocardiography in other major heart disease
Tero-Pekka Alastalo (MD, PhD)
Tero-Pekka Alastalo is the Chief Medical Officer and General Manager of CardioSignal’s operations in the United States. He is based in San Francisco, CA. He has an MD-PhD degree and is specialized in pediatric cardiology. He did his postdoctoral training at Stanford University School of Medicine on the molecular genetic mechanisms of cardiovascular diseases. Tero-Pekka Alastalo is a co-founder of the clinical genetic testing company Blueprint Genetics.
